Back to Journals » International Journal of Nephrology and Renovascular Disease » Volume 5

Thrombotic microangiopathy associated with use of interferon-beta

Authors Olea T, Diaz-Mancebo, Picazo, Martinez Ara, Robles, Selgas R

Received 25 January 2012

Accepted for publication 6 March 2012

Published 15 June 2012 Volume 2012:5 Pages 97—100

DOI https://doi.org/10.2147/IJNRD.S30194

Review by Single-blind

Peer reviewer comments 5


Teresa Olea,1 Raquel Díaz-Mancebo,1 Maria-Luz Picazo,2 Jorge Martínez-Ara,1 Angel Robles,3 Rafael Selgas,1
1Departments of Nephrology, 2Pathology, 3Internal Medicine, Hospital Universitario La Paz, Madrid, Spain

Abstract: Interferon-beta is widely used for the treatment of relapsing multiple sclerosis. The drug is usually well tolerated, but autoimmune adverse effects, including kidney disease, have been reported. Only a few cases of hemolytic uremic syndrome-thrombotic microangiopathy associated interferon-alpha have been described so far, and even fewer with beta-interferon. We report a patient who developed thrombotic microangiopathy during treatment with interferon-beta and improved after discontinuation and steroid therapy. Complement cascade and antiphospholipid antibodies are investigated. The spectrum of renal diseases associated with interferon-beta treatment is also reviewed.

Keywords: thrombotic microangiopathy hemolytic uremic syndrome, multiple sclerosis, interferon-beta

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]